| Study Name | Description | Trial Category | Trial SubCategory Sort descending |
|---|---|---|---|
| EAY191-E5 | This study is for patients who have a KRAS G12C mutation and advanced/metastatic solid tumors. Your cancer must have progressed on standard of care therapy. You cannot have colorectal cancer or non-small cell lung cancer. | Cancer | Solid Tumors |
| EAY191-N4 | The purpose of this study is to compare Selumetinib and Olaparib vs Selumetinib alone. You must be diagnosed with recurrent or persisent Ovarian or Endometiral cancer. Your cancer must have a RAS pathway mutation. | Cancer | Ovarian & Endometrial |
| EAY191-S3 ComboMATCH | The purpose of this study is to determine the effectiveness of Paclitaxel and Ipatasertib in patients who progressed within 6 months of taxane-based therapy. You must have a a AKT-Altered cancer. You must have a locally advanced, unresectable or metastatic cancer. | Cancer | Solid Tumors (non-breast) |
| NRG-GI005 | The purpose of this study is to look at the tumor DNA with blood draws to determine risk of cancer recurrance. You must be diagnosed with Stage 2A colon cancer. | Cancer | Colon |
| NRG-GI008 | The purpose of this study to use blood draws looking at the tumor DNA in the blood to determine need for chemotherapy. You must be diagnosed with stage 3 colon cancer. | Cancer | Colon |
| S2302 | This study is comparing Ramucirumab + Pembrolizumab vs standard of care chemo for patients previously treated with immunotherapy. You must be diagnosed with stage 4 or recurrent Non-Small Cell Lung Cancer (NSCLC). | Cancer | Metastatic Non-Small Cell Lung |
| NRG-LU002 | The purpose of this study is to compare the effectiveness of chemo alone vs SBRT (stereotactic body radiation therapy) and chemo. You must be diagnosed with metastatic non-small cell lung cancer (NSCLC). You must have already received first line therapy. | Cancer | Metastatic Non-Small Cell Lung |
| LUNGMAP | This is a screening study to eavluate biomarker-driven therapies and immunotherapies in previously treated Non-Small Cell Lung Cancer (NSCLC). You must be diagnosed with Stage 4 or recurrent NSCLC. Tissue is sent for screening and patient can be assigned to a sub study based on mutations found. | Cancer | Metastatic Non-Small Cell Lung |
| S1900E (LUNGMAP sub study) | The purpose of this study is determine if the use of Sotorasib is effective in patients with previously treated stage 4 or recuurent KRAS G12C mutated non-squamous non-small cell lung cancer (NSCLC). You must be diagnosed with NSCLC with a KRAS G12C mutation. | Cancer | Metastatic Non-Small Cell Lung |
| S1922 | The purpose of this study is to determine the effectiveness of Ramucirumab and Paclitaxel vs Folfiri chemo. You must be diagnosed with metastatic or unresectable small bowel cancer. | Cancer | Small Bowel |
| S2107 | The purpose of this study is to see if adding immunotherpy to chemo is more effective than chemo alone. You must be diagnosed with metastatic colorectal cancer. | Cancer | Metastatic Colorectal |
| NRG-GI004 | The purpose of this study is to look at the effectiveness of Atezolizumab alone or in combination with other chemo regimens. You must be diagnosed with metastatic colorectal cancer with a DNA mismatch repair deficiency and BRAF gene mutation. | Cancer | Metastatic Colorectal |
| E4512 (sub study A151216) | The purpose of this study is to compare Crizotinib vs observation for patients with a ALK+ Fusion Protein to determine if Crizotinib use results in improved disease-free survival. You must be diagnosed with stage 1B, stage 2 or stage 3A resectable or completely resected non-small cell lung cancer (NSCLC). | Cancer | Non-Small Lung |
| S1608 | This study is for patients who have failed to achieve a complete remission or have relapsed within 2 years after completing treatment. You must have been diagnosed with follicular lymphoma grade 1, 2, or 3. | Cancer | Follicular Lymphoma |
| NRG-HN005 | The purpose of this study is to determine if a reduced dose of radiation therapy is as effective as the standard dose of radiation. You must be diagnosed with P16-Positive Oropharyngeal cancer. Your smoking history must be <10 pack-years. | Cancer | Oropharyngeal |
| EA3161 | This study is comparing maintenance Nivolumab vs observation in patients with locally advance, intermediate risk HPV Positive oropharynx cancer. | Cancer | Oropharyngeal |
| NRG-LU007 | This study is comparing effectiveness of atezolizumab alone vs atezolizumab and radiation. You must be diagnosed with extensive stage small cell lung cancer. | Cancer | Small Cell Lung |
| NRG-GY019 | The purpose of this study is to compare paclitaxel, carboplatin and maintenace letrozole vs letrozole alone. You must be diagnosed with Stage 2-4 serous ovarian cancer. | Cancer | Serous Ovarian |
| EA2176 | The purpose of this study is to see if adding immunotherpy to chemo is more effective than chemo alone. You must be diagnosed with metastatic anal cancer. | Cancer | Metastic Anal |
| Intuitive Surgical Ureter | The purpose of this study is to investigate whether the study drug may allow the surgeon to better see the ureters when using the da Vinci Surgical System for gynecological surgery. | Surgery | Gynecology |
| SOUL Music | This is a multicenter prospective trial with randomized and observational cohorts assessing patient-reported outcomes and unplanned healthcare utilization following ureteroscopic treatment of renal and ureteral stones, with placement versus omission of a ureteral stent. Eligible participants in the randomization trial will be randomized to ureteroscopy with stent placement or stent omission. Eligible participants that consent to the observational only cohort will complete surveys and the treating physicians will decide the treatment options for the participants. | Surgery | Urinary Stone Disease |
| Tandem | The purpose of this study is to compare the effects of the study drug, obicetrapib when administered together with the drug ezetimibe as a fixed dose combination. A fixed dose combination means the two drugs are combined into a single tablet. The study will also check how safe obicetrapib and ezetimibe is for participants with high levels of LDL-C in the blood. | Heart & Vascular | Lipid Management; Cardiovascular Disease |
| A032002 | The purpose of this study is to compare immunotherapy alone vs immunotherapy in combination with radiation for patients with metastatic Urothelial cancer. | Cancer | Metastatic Urothelial |
| A032103 | The purpose of this study is to use central DNA testing to monitor recurrance in patients with urothelial cancer. You must have had a radical cysectomy and lymph node dissection with no evidence of residual cancer. | Cancer | Urothelial |
| EAY191-N5 | This study is for patient's who have HER2+ gynecologic cancers or other solid tumors. Cannot have breast cancer. You must have recurrent disease or progressed on treatment. | Cancer | Her2+ Solid Tumors |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.